Infund Holding Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chen Ding

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.8yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO

Chen Ding (49 yo)

2.8yrs

Tenure

CN¥757,600

Compensation

Mr. Chen Ding is General Manager of Infund Holding Co., Ltd. since December 15, 2021 and has been its Director since October 09, 2023.

Board Members

Name	Position	Tenure	Compensation	Ownership
Chen Ding	GM & Director	less than a year	CN¥757.60k	no data
Wen Bin Xie	CFO & Director	5yrs	CN¥623.60k	no data
Yangyu Zhang	Deputy GM & Director	4.7yrs	CN¥757.60k	no data
Rongjie Wan	Deputy GM & Director	4.7yrs	CN¥120.00k	no data
Yanchang Deng	Independent Director	10yrs	CN¥180.00k	no data
Rong Liang	Independent Director	4.3yrs	CN¥180.00k	no data
Taozi Han	Chairman	5yrs	CN¥868.00k	no data
Tielin Wang	Independent Director	5yrs	CN¥180.00k	no data
Guangxu Wang	Chairman of the Supervisory Board	5yrs	no data	no data
Shilian Xiao	Independent Director	less than a year	no data	no data

4.8yrs

Average Tenure

49yo

Average Age

Experienced Board: 002141's board of directors are considered experienced (4.8 years average tenure).

Infund Holding Management

Management criteria checks 1/4

Key information

Recent management updates

Infund Holding Co., Ltd., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Infund Holding Co., Ltd. Approves Board Appointments

Insufficient new directors

High number of new directors

High number of new and inexperienced directors

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.008 (vs CN¥0.025 loss in 2Q 2023)

Infund Holding Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Infund Holding Co., Ltd. (SZSE:002141) announces an Equity Buyback for CNY 100 million worth of its shares.

Infund Holding Co., Ltd., Annual General Meeting, May 16, 2024

Full year 2023 earnings released: CN¥0.11 loss per share (vs CN¥0.20 profit in FY 2022)

Investor sentiment deteriorates as stock falls 24%

New major risk - Share price stability

Infund Holding Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment improves as stock rises 17%

New minor risk - Financial data availability

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Less than half of directors are independent

Infund Holding Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.20 profit in 3Q 2022)

Infund Holding Co., Ltd. Approves Board Appointments

Infund Holding Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: CN¥0.023 loss per share (vs CN¥0.005 profit in 2Q 2022)

Infund Holding Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023

Full year 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.027 in FY 2021)

Insufficient new directors

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.008 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.005 (vs CN¥0.004 in 2Q 2021)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Infund Holding Co., Ltd., Annual General Meeting, May 06, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS CN¥0.008 (vs CN¥0.04 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.004 (vs CN¥0.13 loss in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.004 (vs CN¥0.001 in 1Q 2020)

Full year 2020 earnings released: CN¥0.48 loss per share (vs CN¥0.007 profit in FY 2019)

Infund Holding Co., Ltd. (SZSE:002141) and Shiji Biotechnology (Nanjing) Co., Ltd. signed an agreement to acquire Chengdu Tianbang Biological Products Co., Ltd. from Shiji Biotechnology (Nanjing) Co., Ltd. for CNY 460 million.

Infund Holding Co., Ltd. to Report Fiscal Year 2020 Results on Apr 15, 2021

New 90-day low: CN¥2.02

New 90-day low: CN¥2.46

Third quarter earnings released

New 90-day low: CN¥2.97

Infund Holding Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Infund Holding Co., Ltd. Approves Appointment of Directors

New 90-day low: CN¥3.04

First half earnings released

New 90-day high - CN¥3.82

Infund Holding Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥3.61

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age